143 related articles for article (PubMed ID: 37552126)
1. Cyclin-dependent kinase-9 in B-cell malignancies: pathogenic role and therapeutic implications.
Dominguez EC; Roleder C; Ball B; Danilov AV
Leuk Lymphoma; 2023 Dec; 64(12):1893-1904. PubMed ID: 37552126
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase 9 (Cdk9) of fission yeast is activated by the CDK-activating kinase Csk1, overlaps functionally with the TFIIH-associated kinase Mcs6, and associates with the mRNA cap methyltransferase Pcm1 in vivo.
Pei Y; Du H; Singer J; Stamour C; Granitto S; Shuman S; Fisher RP
Mol Cell Biol; 2006 Feb; 26(3):777-88. PubMed ID: 16428435
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis.
Wang K; Hampson P; Hazeldine J; Krystof V; Strnad M; Pechan P; M J
PLoS One; 2012; 7(1):e30128. PubMed ID: 22276149
[TBL] [Abstract][Full Text] [Related]
4. Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma.
Zhang Y; Zhou L; Leng Y; Dai Y; Orlowski RZ; Grant S
Oncotarget; 2017 Aug; 8(35):59476-59491. PubMed ID: 28938651
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
6. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
Bose P; Simmons GL; Grant S
Expert Opin Investig Drugs; 2013 Jun; 22(6):723-38. PubMed ID: 23647051
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation.
Mbonye U; Wang B; Gokulrangan G; Shi W; Yang S; Karn J
J Biol Chem; 2018 Jun; 293(26):10009-10025. PubMed ID: 29743242
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
Kapasi AJ; Spector DH
J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543
[TBL] [Abstract][Full Text] [Related]
10. CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA.
Garber ME; Mayall TP; Suess EM; Meisenhelder J; Thompson NE; Jones KA
Mol Cell Biol; 2000 Sep; 20(18):6958-69. PubMed ID: 10958691
[TBL] [Abstract][Full Text] [Related]
11. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A
Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145
[TBL] [Abstract][Full Text] [Related]
12. TFIIH and P-TEFb coordinate transcription with capping enzyme recruitment at specific genes in fission yeast.
Viladevall L; St Amour CV; Rosebrock A; Schneider S; Zhang C; Allen JJ; Shokat KM; Schwer B; Leatherwood JK; Fisher RP
Mol Cell; 2009 Mar; 33(6):738-51. PubMed ID: 19328067
[TBL] [Abstract][Full Text] [Related]
13. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription.
Zhou M; Halanski MA; Radonovich MF; Kashanchi F; Peng J; Price DH; Brady JN
Mol Cell Biol; 2000 Jul; 20(14):5077-86. PubMed ID: 10866664
[TBL] [Abstract][Full Text] [Related]
14. CDK9 keeps RNA polymerase II on track.
Egloff S
Cell Mol Life Sci; 2021 Jul; 78(14):5543-5567. PubMed ID: 34146121
[TBL] [Abstract][Full Text] [Related]
15. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
Węsierska-Gądek J; Kramer MP
Expert Opin Investig Drugs; 2011 Dec; 20(12):1611-28. PubMed ID: 22017180
[TBL] [Abstract][Full Text] [Related]
16. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
Caracciolo V; Laurenti G; Romano G; Carnevale V; Cimini AM; Crozier-Fitzgerald C; Gentile Warschauer E; Russo G; Giordano A
Cell Cycle; 2012 Mar; 11(6):1202-16. PubMed ID: 22391209
[TBL] [Abstract][Full Text] [Related]
17. Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.
Kobayashi M; Takahashi-Suzuki I; Shimomura T; Iwasawa Y; Hirai H
Invest New Drugs; 2011 Oct; 29(5):921-31. PubMed ID: 20524038
[TBL] [Abstract][Full Text] [Related]
18. Targeting cyclin-dependent kinase 9 in cancer therapy.
Shen YL; Wang YM; Zhang YX; Ma SJ; Yang LH; Zhao CG; Huang XY
Acta Pharmacol Sin; 2022 Jul; 43(7):1633-1645. PubMed ID: 34811514
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional activity of positive transcription elongation factor b kinase in vivo requires the C-terminal domain of RNA polymerase II.
Napolitano G; Majello B; Licciardo P; Giordano A; Lania L
Gene; 2000 Aug; 254(1-2):139-45. PubMed ID: 10974544
[TBL] [Abstract][Full Text] [Related]
20. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation.
Baumli S; Lolli G; Lowe ED; Troiani S; Rusconi L; Bullock AN; Debreczeni JE; Knapp S; Johnson LN
EMBO J; 2008 Jul; 27(13):1907-18. PubMed ID: 18566585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
